The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Effect of Corticosteroids on Treatment Failure Among Hospitalized Patients With Severe Community-Acquired Pneumonia and High Inflammatory Response: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: In patients with severe community-acquired pneumonia, treatment failure is associated with excessive inflammatory response and worse outcomes. Corticosteroids may modulate cytokine release in these patients, but the benefit of this adjunctive therapy remains controversial. OBJECTIVE: To assess the effect of corticosteroids in patients with severe community-acquired pneumonia and high associated inflammatory response. DESIGN, SETTING, AND PARTICIPANTS: Multicenter, randomized, double-blind, placebo-controlled trial conducted in 3 Spanish teaching hospitals involving patients with both severe community-acquired pneumonia and a high inflammatory response, which was defined as a level of C-reactive protein greater than 150 mg/L at admission. Patients were recruited and followed up from June 2004 through February 2012. INTERVENTIONS: Patients were randomized to receive either an intravenous bolus of 0.5 mg/kg per 12 hours of methylprednisolone (n = 61) or placebo (n = 59) for 5 days started within 36 hours of hospital admission. MAIN OUTCOMES AND MEASURES: The primary outcome was treatment failure (composite outcome of early treatment failure defined as [1] clinical deterioration indicated by development of shock, [2] need for invasive mechanical ventilation not present at baseline, or [3] death within 72 hours of treatment; or composite outcome of late treatment failure defined as [1] radiographic progression, [2] persistence of severe respiratory failure, [3] development of shock, [4] need for invasive mechanical ventilation not present at baseline, or [5] death between 72 hours and 120 hours after treatment initiation; or both early and late treatment failure). In-hospital mortality was a secondary outcome and adverse events were assessed. RESULTS: There was less treatment failure among patients from the methylprednisolone group (8 patients [13%]) compared with the placebo group (18 patients [31%]) (P = .02), with a difference between groups of 18% (95% CI, 3% to 32%). Corticosteroid treatment reduced the risk of treatment failure (odds ratio, 0.34 [95% CI, 0.14 to 0.87]; P = .02). In-hospital mortality did not differ between the 2 groups (6 patients [10%] in the methylprednisolone group vs 9 patients [15%] in the placebo group; P = .37); the difference between groups was 5% (95% CI, -6% to 17%). Hyperglycemia occurred in 11 patients (18%) in the methylprednisolone group and in 7 patients (12%) in the placebo group (P = .34). CONCLUSIONS AND RELEVANCE: Among patients with severe community-acquired pneumonia and high initial inflammatory response, the acute use of methylprednisolone compared with placebo decreased treatment failure. If replicated, these findings would support the use of corticosteroids as adjunctive treatment in this clinical population. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00908713.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511159 · Cited by 6,202
Self-citationA Prediction Rule to Identify Low-Risk Patients with Community-Acquired Pneumonia
Fine, M. J., Auble, T. E., Yealy, D. M., Hanusa, B. H., Weissfeld, L. A., Singer, D. E., Coley, C. M., Marrie, T. J., & Kapoor, W. N. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701233360402 · Cited by 4,582
Antiinflammatory Action of Glucocorticoids — New Mechanisms for Old Drugs
Rhen, T., & Cidlowski, J. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra050541 · Cited by 3,149
Hydrocortisone Therapy for Patients with Septic Shock
Sprung, C. L., Annane, D., Keh, D., Moreno, R., Singer, M., Freivogel, K., Weiss, Y. G., Benbenishty, J., Kalenka, A., Forst, H., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa071366 · Cited by 2,132
Prognosis and Outcomes of Patients With Community-Acquired Pneumonia: A Meta-analysis
Fine, M. J. (1996) · JAMA · doi:10.1001/jama.1996.03530260048030 · Cited by 1,310
Hydrocortisone Infusion for Severe Community-acquired Pneumonia: A Preliminary Randomized Study
Confalonieri, M., Urbino, R., Potena, A., Piattella, M., Parigi, P., Puccio, G., Della Porta, R., Giorgio, C., Blasi, F., Umberger, R., et al. (2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200406-808oc · Cited by 857
Risk of Infectious Complications in Patients Taking Glucocorticosteroids
Stuck, A. E., Minder, C. E., & Frey, F. J. (1989) · Clinical Infectious Diseases · doi:10.1093/clinids/11.6.954 · Cited by 836
Halm, E. A., Fine, M. J., Marrie, T. J., Coley, C. M., Kapoor, W. N., Obrosky, D. S., & Singer, D. E. (1998) · JAMA · doi:10.1001/jama.279.18.1452 · Cited by 518
The late phase of sepsis is characterized by an increased microbiological burden and death rate
Otto, G. P., Sossdorf, M., Claus, R. A., Rödel, J., Menge, K., Reinhart, K., Bauer, M., & Riedemann, N. C. (2011) · Critical Care · doi:10.1186/cc10332 · Cited by 434
A PREDICTION RULE TO IDENTIFY LOW-RISK PATIENTS WITH COMMUNITY- ACQUIRED PNEUMONIA
Ine, J. F., Uble, T. H. E. A., Onald, D., Ealy, M., Anusa, B. A. H. H., Eissfeld, L. I. A. W., Inger, D. A. E. S., Oley, C. H. M. C., Arrie, T. H. J. M., Ishwa, W., et al. (2011) · Cited by 424
Meijvis, S. C., Hardeman, H., Remmelts, H. H., Heijligenberg, R., Rijkers, G. T., van Velzen-Blad, H., Voorn, G. P., van de Garde, E. M., Endeman, H., Grutters, J. C., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60607-7 · Cited by 366
Prognosis and outcomes of patients with community-acquired pneumonia. A meta-analysis
Fine, M. J. (1996) · JAMA · doi:10.1001/jama.275.2.134 · Cited by 337
Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome
Menendez, R. (2004) · Thorax · doi:10.1136/thx.2003.017756 · Cited by 319
Self-citationSnijders, D., Daniels, J. M. A., de Graaff, C. S., van der Werf, T. S., & Boersma, W. G. (2010) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200905-0808oc · Cited by 295
Effects of systemic steroids in patients with severe community-acquired pneumonia
Garcia-Vidal, C., Calbo, E., Pascual, V., Ferrer, C., Quintana, S., & Garau, J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00027607 · Cited by 290
Restrepo, M. I., Mortensen, E. M., Rello, J., Brody, J., & Anzueto, A. (2010) · Chest · doi:10.1378/chest.09-1547 · Cited by 223
Self-citationA Comparative Study of Community-Acquired Pneumonia Patients Admitted to the Ward and the ICU
Restrepo, M. I., Mortensen, E. M., Velez, J. A., Frei, C., & Anzueto, A. (2008) · Chest · doi:10.1378/chest.07-1456 · Cited by 220
Self-citationMarkers of treatment failure in hospitalised community acquired pneumonia
Menendez, R., Cavalcanti, M., Reyes, S., Mensa, J., Martinez, R., Marcos, M. A., Filella, X., Niederman, M., & Torres, A. (2008) · Thorax · doi:10.1136/thx.2007.086785 · Cited by 184
Self-citationPatterns of Cytokine Expression in Community-Acquired Pneumonia
Puren, A. J., Feldman, C. H., Savage, N., Becker, P. J., & Smith, C. A. (1995) · CHEST Journal · doi:10.1378/chest.107.5.1342 · Cited by 148
Community-acquired polymicrobial pneumonia in the intensive care unit: aetiology and prognosis
Cillóniz, C., Ewig, S., Ferrer, M., Polverino, E., Gabarrús, A., de la Bellacasa, J. P., Mensa, J., & Torres, A. (2011) · Critical Care · doi:10.1186/cc10444 · Cited by 133
Self-citationPneumonia Severity Index Class V Patients With Community-Acquired Pneumonia
Valencia, M., Badia, J. R., Cavalcanti, M. A. D. N., Ferrer, M., Agustí, C., Angrill, J., García, E., Mensa, J., Niederman, M. S., & Torres, A. (2007) · CHEST Journal · doi:10.1378/chest.07-0306 · Cited by 112
Self-citationCorticosteroids in the Treatment of Community-Acquired Pneumonia in Adults: A Meta-Analysis
Nie, W., Zhang, Y., Cheng, J.-W., & Xiu, Q. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047926 · Cited by 108
Ramírez, P., Ferrer, M., Martí, V., Reyes, S., Martínez, R., Menéndez, R., Ewig, S., & Torres, A. (2011) · Critical Care Medicine · doi:10.1097/ccm.0b013e3182257445 · Cited by 104
Self-citationTalbot, G. H., Powers, J. H., Fleming, T. R., Siuciak, J. A., Bradley, J. S., Boucher, H. W., & on behalf of the CABP-ABSSSI Project Team (2012) · Clinical Infectious Diseases · doi:10.1093/cid/cis566 · Cited by 84
Effects of glucocorticoids in ventilated piglets with severe pneumonia
Sibila, O., Luna, C. M., Agustı́, C., Baquero, S., Gando, S., Patrón, J. R., Morato, J. G., Absi, R., Bassi, N., & Torres, A. (2008) · European Respiratory Journal · doi:10.1183/09031936.00009208 · Cited by 68
Self-citationHydrocortisone Therapy for Patients with Septic Shock
Ledges, M. (2008) · Journal of Emergency Medicine · doi:10.1016/j.jemermed.2008.03.023 · Cited by 44
Li, Y., Cui, X., Li, X., Solomon, S. B., Danner, R. L., Banks, S. M., Fitz, Y., Annane, D., Natanson, C., & Eichacker, P. Q. (2007) · Intensive Care Medicine · doi:10.1007/s00134-007-0921-7 · Cited by 39
Biomarkers define the clinical response to dexamethasone in community-acquired pneumonia
Remmelts, H. H. F., Meijvis, S. C. A., Heijligenberg, R., Rijkers, G. T., Oosterheert, J. J., Bos, W. J. W., Endeman, H., Grutters, J. C., Hoepelman, A. I. M., & Biesma, D. H. (2012) · Journal of Infection · doi:10.1016/j.jinf.2012.03.008 · Cited by 34
Severe community-acquired pneumonia
Álvarez-Lerma, F., & Torres, A. (2004) · Current Opinion in Critical Care · doi:10.1097/01.ccx.0000140949.05643.34 · Cited by 31
Self-citationNawab, Q.-U.-A., Golden, E. B., Confalonieri, M., Umberger, R. A., & Meduri, G. U. (2011) · Intensive Care Medicine · doi:10.1007/s00134-011-2274-5 · Cited by 27
Is Prolonged Low-Dose Glucocorticoid Treatment Beneficial in Community-Acquired Pneumonia?
Confalonieri, M., Annane, D., Antonaglia, C., Santagiuliana, M., Borriello, E. M., & Meduri, G. U. (2013) · Current Infectious Disease Reports · doi:10.1007/s11908-013-0322-8 · Cited by 22
Cited by
Metlay, J. P., Waterer, G. W., Long, A. C., Anzueto, A., Brozek, J., Crothers, K., Cooley, L. A., Dean, N. C., Fine, M. J., Flanders, S. A., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201908-1581st · Cited by 3,657
“Differences have been observed in the time to resolution of fever and other features of clinical stability, but these have not translated into differences in mortality, length of stay, or organ failure (172, 173).”
BackgroundSelf-citationHotchkiss, R. S., Moldawer, L. L., Opal, S. M., Reinhart, K., Turnbull, I. R., & Vincent, J.-L. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.45 · Cited by 1,620
Corticosteroid Therapy for Critically Ill Patients with Middle East Respiratory Syndrome
Arabi, Y. M., Mandourah, Y., Al-Hameed, F., Sindi, A. A., Almekhlafi, G. A., Hussein, M. A., Jose, J., Pinto, R., Al-Omari, A., Kharaba, A., et al. (2018) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201706-1172oc · Cited by 1,122
Liu, W., Tao, Z.-W., Wang, L., Yuan, M.-L., Liu, K., Zhou, L., Wei, S., Deng, Y., Liu, J., Liu, H.-G., et al. (2020) · Chinese Medical Journal · doi:10.1097/cm9.0000000000000775 · Cited by 1,104
Torres, A., Cilloniz, C., Niederman, M. S., Menéndez, R., Chalmers, J. D., Wunderink, R. G., & van der Poll, T. (2021) · Nature Reviews Disease Primers · doi:10.1038/s41572-021-00259-0 · Cited by 798
Self-citation
Metadata
- Authors
- Torres, A., Sibila, O., Ferrer, M., Polverino, E., Menendez, R., Mensa, J., Gabarrús, A., Sellarés, J., Restrepo, M. I., Anzueto, A., Niederman, M. S., & Agustí, C.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-02-17
- Volume
- 313
- Issue
- 7
- Pages
- 677
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2142413409
- Cited by
- 571
- References
- 31
- FWCI
- 45.18
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.